Journal Mobile Options
Table of Contents
Vol. 80, No. 1, 2007
Issue release date: June 2007
Pharmacology 2007;80:49–56
(DOI:10.1159/000103097)

Behavioral Evaluation of Male and Female Mice Pups Exposed to Fluoxetine during Pregnancy and Lactation

Lisboa S.F.S. · Oliveira P.E. · Costa L.C. · Venâncio E.J. · Moreira E.G.
Departments of aPhysiological Sciences and bPathological Sciences, State University of Londrina, Londrina, Brazil

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background/Aims: Fluoxetine (FLX) has been widely prescribed for depression during pregnancy and/or lactation. Since serotonin is a neurotrophic factor, the use of FLX by mothers could disrupt brain development resulting in behavioral alterations in their progeny. This study evaluated the effects of developmental FLX exposure on anxiety, depression, aggressivity and pain sensitivity of male and female mice pups. Methods: Swiss dams were treated daily, by gavage, with 7.5 mg/kg of FLX during pregnancy and lactation. Pups were submitted to open-field, forced swimming, elevated plus-maze, intruder-resident and hot plate tests at adolescence and adulthood. Results and Conclusion: In male pups, exposure to FLX decreased ambulation at postnatal day (PND) 40 and tended (p = 0.07) to increase the latency to the first attack in the intruder-resident test at PND 70, suggesting decreased impulsivity. In female pups, FLX exposure increased immobility time in the forced swimming test at both PND 30 and 70, which is interpreted as depressive-like behavior. In conclusion, our results suggest that maternal exposure to FLX during pregnancy and lactation results in enduring behavioral alterations in male and female pups throughout life.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Burt VK, Stein K: Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 2002;63:9–15.
  2. Sloan DM, Kornstein SG: Gender differences in depression and response to antidepressant treatment. Psychiatr Clin North Am 2003;26:581–594.
  3. McElhatton PR: Drug use in pregnancy. Part 1. Pharm J 2003;270:270–272.
  4. Evans J, Heron J, Francomb H, Oke S, Golding J: Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001;323:257–260.
  5. Zeskind PS, Stephens LE: Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375.
  6. American Academy of Pediatrics Committee on Drugs: Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 2000;105:880–887.
  7. Einarson A, Koren G: New antidepressants in pregnancy. Can Fam Physician 2004;50:227–229.
  8. Pohland RC, Byrd TK, Hamilton M, Koons JR: Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989;98:198–205.
  9. Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A, et al: Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biol Psychiatry 2001;50:775–782.
  10. Lauder JM: Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci 1993;16:233–240.
  11. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM: Serotonin as a developmental signal. Behav Brain Res 1996;73:19–29.
  12. De Ceballos ML, Benedi A, Urdin C, Del Rio J: Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT2 receptors in cerebral cortex: lack of correlation between 5-HT2 receptors and serotonin-mediated behaviour. Neuropharmacology 1985;24:947–952.
  13. Jason KM, Cooper TB, Friedman E: Prenatal exposure to imipramine alters early behavioral development and beta adrenergic receptors in rats. J Pharmacol Exp Ther 1981;217:461–466.
  14. Ansorge MS, Zhou M, Lira A, Hen R, Gingrish JA: Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004;306:879–881.
  15. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH: Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 1998;95:15049–15054.
  16. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M: Increased anxiety of mice lacking the serotonin 1A receptor. Proc Natl Acad Sci USA 1998;95:10734–10739.
  17. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelson M: Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci USA 1998;95:14476–14481.
  18. Bairy KL, Madhyastha S, Ashok KP, Bairy I, Malini S: Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 2006;79:1–11.
  19. Hoyt JA, Byrd RA, Brophy GT, Markham JK: A reproduction study of fluoxetine hydrochloride administered in the diet to rats. Teratology 1989;39:459–465.
  20. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher E, Moran MS, Buelke-Sam J: A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol 1994;23:194–205.
  21. Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RCS, Paul IA: Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006;31:47–57.
  22. Organization for Economic Co-operation and Development: OECD Guideline for the Testing of Chemicals. Developmental Neurotoxicity Study 426. pp. 1–20, Organization for Economic Co-operation and Development, 2003.
  23. Broadhurst PL: Experiments in psychogenetics; in Eysenk HJ (ed): Experiments in Personality. London, Rutledge and Kegan Paul, 1960, pp 31–61.
  24. Porsolt RD, Le Pichon M, Jalfre M: Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730–732.
  25. Lister RG: The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987;92:180–185.
  26. Olivier B, Mos J, Van Oorschot R, Hen R: Serotonin receptors and animal models of aggressive behavior. Pharmacopsychiatry 1995;28:80–90.
  27. Eddy NB, Leimbach D: Synthetic analgesics. 2. Dithienylbutenyl- and dithienylbutylamines. J Pharmacol Exp Ther 1953;107:385–393.
  28. Byrd RA, Markham JK: Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994;22:511–518.
  29. Nelson RJ, Demas GE, Huang PL, Fishman MC, Dawson VL, Dawson TM, Snyder SH: Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature 1995;378:383–386.
  30. Zhuang X, Gross C, Santarelli L, Compan V, Trillat AC, Hen R: Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 1999;21:S52–S60.
  31. Willner P: The validity of animal models of depression. Psychopharmacology 1984;83:1–16.
  32. Hansen HH, Sanchez C, Meier E: Neonatal administration of the selective serotonin reuptake inhibitor Lu 10-134-C increases forced swimming-induced immobility in adult rats: a putative animal model of depression? J Pharmacol Exp Ther 1997;283:1333–1341.
  33. Mendes-da-Silva C, Souza SL, Barreto-Medeiros JM, Freitas-Silva SR, Antunes DEC, Cunha ADU, et al: Neonatal treatment with fluoxetine reduces depressive behavior induced by forced swim in adult rats. Arq Neuropsiquiatr 2002;60:928–931.
  34. Manhães de Castro R, Barreto Medeiros JM, Mendes da Silva C, Ferreira LMP, Guedes RCA, Cabral Filho JE, Costa JA: Reduction of intraspecific aggression in adult rats by neonatal treatment with a selective serotonin reuptake inhibitor. Braz J Med Biol Res 2001;34:121–124.
  35. Lauder JM, Liu J, Grayson DR: In utero exposure to serotoninergic drugs alters neonatal expression of 5-HT1A receptor transcripts: a quantitative RT-PCR study. Int J Dev Neurosci 2000;18:171–176.
  36. Albert PR, Zhou QY, Van Tol HH, Bunzow JR, Civelli O: Cloning, functional expression and mRNA tissue distribution of the rat 5-hydroxytryptamine1A receptor gene. J Biol Chem 1990;265:5825–5832.
  37. Daval G, Verge D, Becerril A, Gozlan H, Spampinato U, Hamon M: Transient expression of 5-HT1A receptor binding sites in some areas of the rat CNS during postnatal development. Int J Dev Neurosci 1987;5:171–180.
  38. Del Olmo E, Diaz A, Guirao-Pineyro M, Del Arco C, Pascual J, Pazos A: Transient localization of 5-HT1A receptors in human cerebellum during development. Neurosci Lett 1994;166:149–152.
  39. Borella A, Brinda M, Whitaker-Azmitia PM: Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies. Neuropharmacology 1997;36:445–450.
  40. Wilson CC, Faber KM, Haring JH: Serotonin regulates synaptic connections in the dentate molecular layer of adult rats via 5-HT1A receptors: evidence for a glial mechanism. Brain Res 1998;782:235–239.
  41. Yan W, Wilson CC, Haring JH: 5-HT1A receptors mediate the neurotrophic effect of serotonin on developing dentate granule cells. Brain Res Dev Brain Res 1997;98:185–190.
  42. Albert PR, Lemonde S: 5-HT1A receptors, gene repression and depression: guilt by association. Neuroscientist 2004;10:575–593.
  43. Giammanco M, Tabacchi G, Giammanco S, Di Majo D, La Guardia M: Testosterone and aggressiveness. Med Sci Monit 2005;11:RA136–RA145.
  44. Nelson RJ, Chiavegatto S: Molecular basis of aggression.Trends Neurosci 2001;24:713–719.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50